Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FRX Forest Road Acquisition		$10.30	$9.72 ▼ $18.20	$450M	N/A	2.07 million shs	40,482 shs
NKTR Nektar Therapeutics	$24.94 -6.5%	$15.75	$6.48 ▼ $37.38	$330.89M	0.94	521,697 shs	1.10 million shs
OMER Omeros	$3.36 -3.4%	$3.44	$2.95 ▼ $13.60	$203.90M	2.16	745,999 shs	681,132 shs
PCRX Pacira BioSciences	$21.59 -3.1%	$24.61	$11.16 ▼ $27.64	$1.03B	0.48	886,893 shs	601,123 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FRX Forest Road Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
NKTR Nektar Therapeutics	+10.48%	+6.25%	+205.50%	+179.38%	+22.62%
OMER Omeros	-0.85%	+0.58%	+8.41%	-48.67%	-33.08%
PCRX Pacira BioSciences	-1.37%	-5.91%	-8.61%	-9.57%	+6.19%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	4.0798 of 5 stars	3.4	2.0	0.0	4.2	3.1	2.5	0.0
OMER Omeros	3.7928 of 5 stars	3.4	0.0	0.0	4.4	2.8	1.7	0.6
PCRX Pacira BioSciences	3.1119 of 5 stars	2.2	1.0	0.0	3.9	2.0	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FRX Forest Road Acquisition	0.00	N/A	N/A	N/A
NKTR Nektar Therapeutics	2.86	Moderate Buy	$88.33	254.18% Upside
OMER Omeros	2.83	Moderate Buy	$18.00	435.71% Upside
PCRX Pacira BioSciences	2.33	Hold	$26.44	22.48% Upside

Current Analyst Ratings Breakdown

Latest FRX, PCRX, NKTR, and OMER Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	NKTR Nektar Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $85.00
6/30/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/27/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/24/2025	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$60.00 ➝ $100.00
6/24/2025	NKTR Nektar Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$120.00
6/10/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/16/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
5/12/2025	NKTR Nektar Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/9/2025	PCRX Pacira BioSciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $30.00
5/7/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	$0.56 per share	N/A
NKTR Nektar Therapeutics	$98.43M	3.14	N/A	N/A	$4.94 per share	5.05
OMER Omeros	N/A	N/A	N/A	N/A	($3.15) per share	N/A
PCRX Pacira BioSciences	$700.97M	1.43	$4.18 per share	5.16	$16.86 per share	1.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FRX Forest Road Acquisition	-$7.92M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	-$118.96M	-$9.60	N/A	N/A	N/A	-152.49%	-329.54%	-55.24%	8/6/2025 (Estimated)
OMER Omeros	-$156.82M	-$2.65	N/A	N/A	N/A	N/A	N/A	-59.68%	8/6/2025 (Estimated)
PCRX Pacira BioSciences	-$99.56M	-$2.28	N/A	8.40	N/A	-14.78%	13.78%	7.00%	7/29/2025 (Estimated)

Latest FRX, PCRX, NKTR, and OMER Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	NKTR Nektar Therapeutics	-$2.58	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	OMER Omeros	-$0.46	N/A	N/A	N/A	$0.31 million	N/A
7/29/2025	Q2 2025	PCRX Pacira BioSciences	$0.73	N/A	N/A	N/A	$183.11 million	N/A
5/15/2025	Q1 2025	OMER Omeros	-$0.60	-$0.65	-$0.05	-$0.58	$0.40 million	N/A
5/8/2025	Q1 2025	NKTR Nektar Therapeutics	-$2.70	-$3.30	-$0.60	-$0.24	$15.61 million	$10.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FRX Forest Road Acquisition	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
PCRX Pacira BioSciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FRX Forest Road Acquisition	N/A	0.37	0.37
NKTR Nektar Therapeutics	N/A	3.24	3.24
OMER Omeros	N/A	1.16	1.16
PCRX Pacira BioSciences	0.48	2.41	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FRX Forest Road Acquisition	N/A
NKTR Nektar Therapeutics	75.88%
OMER Omeros	48.79%
PCRX Pacira BioSciences	99.73%

Insider Ownership

Company	Insider Ownership
FRX Forest Road Acquisition	N/A
NKTR Nektar Therapeutics	5.25%
OMER Omeros	12.90%
PCRX Pacira BioSciences	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FRX Forest Road Acquisition	N/A	37.50 million	N/A	Not Optionable
NKTR Nektar Therapeutics	220	12.41 million	11.76 million	Optionable
OMER Omeros	210	58.59 million	51.04 million	Optionable
PCRX Pacira BioSciences	720	46.29 million	43.33 million	Optionable

FRX, PCRX, NKTR, and OMER Headlines

Recent News About These Companies

Investors who lost money with shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation in connection with Lawsuit

July 16 at 8:40 AM | prnewswire.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Consensus Rating of "Hold" by Brokerages

July 13, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Makes New $277,000 Investment in Pacira BioSciences, Inc. (NASDAQ:PCRX)

July 12, 2025 | marketbeat.com

Non-opioid pain drug maker Pacira lays off 71 in California, retires facility in manufacturing upgrade

July 11, 2025 | fiercepharma.comF

Pacira BioSciences to Close Manufacturing Suite, Lay Off 71 Employees

July 10, 2025 | marketwatch.com

Pacira announces layoffs due to efficiencies in Exparel production

July 10, 2025 | msn.com

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 3, 2025 | globenewswire.com

Robeco Institutional Asset Management B.V. Purchases 12,750 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

July 2, 2025 | marketbeat.com

Pacira BioSciences Debuts Inspiring New Film Highlighting One Patient’s Journey to Pain Relief and Innovation in Care at BIO 2025

June 18, 2025 | finance.yahoo.com

Is the Options Market Predicting a Spike in Pacira BioSciences Stock?

June 18, 2025 | zacks.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Rating of "Hold" from Analysts

June 18, 2025 | marketbeat.com

PACIRA ALERT: Bragar Eagel & Squire, P.C. is Investigating Pacira BioSciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

June 17, 2025 | globenewswire.com

Pacira Pharmaceuticals Stockholders Approve Amended Incentive Plan

June 13, 2025 | tipranks.com

Pacira BioSciences, Inc. (PCRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

June 8, 2025 | accessnewswire.comA

Lauren Riker Sells 5,578 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) Stock

June 7, 2025 | insidertrades.com

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

Pacira BioSciences’s First Quarter 2025 Misses Estimates

May 29, 2025 | ryortho.comR

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

May 25, 2025 | accessnewswire.comA

Pacira at RBC Conference: Strategic Growth and Gene Therapy Focus

May 23, 2025 | uk.investing.com

Pacira BioSciences (NASDAQ:PCRX) adds US$78m to market cap in the past 7 days, though investors from three years ago are still down 57%

May 22, 2025 | finance.yahoo.com

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

May 14, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
By Nathan Reiff | June 30, 2025
View Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
By Leo Miller | June 28, 2025
View Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?

FRX, PCRX, NKTR, and OMER Company Descriptions

Forest Road Acquisition NYSE:FRX

Forest Road Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the technology, media, and telecommunications space. The company was founded in 2020 and is based in New York, New York.

Nektar Therapeutics NASDAQ:NKTR

$24.94 -1.73 (-6.49%)

Closing price 04:00 PM Eastern

Extended Trading

$24.62 -0.33 (-1.30%)

As of 07:59 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Omeros NASDAQ:OMER

$3.36 -0.12 (-3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$3.50 +0.14 (+4.17%)

As of 07:59 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Pacira BioSciences NASDAQ:PCRX

$21.59 -0.70 (-3.14%)

Closing price 04:00 PM Eastern

Extended Trading

$21.58 0.00 (-0.02%)

As of 07:19 PM Eastern

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time